Skip to main content

previous disabled Page of 867
and
  1. Article

    Open Access

    Template-independent enzymatic synthesis of RNA oligonucleotides

    RNA oligonucleotides have emerged as a powerful therapeutic modality to treat disease, yet current manufacturing methods may not be able to deliver on anticipated future demand. Here, we report the development...

    Daniel J. Wiegand, Jonathan Rittichier, Ella Meyer, Howon Lee in Nature Biotechnology (2024)

  2. No Access

    Article

    Enzymatic synthesis of RNA oligonucleotides

    Research on enzymatic RNA synthesis has long been eclipsed by work on DNA—but a new method provides a leap forward for RNA.

    Marcel Hollenstein in Nature Biotechnology (2024)

  3. Article

    Open Access

    Precise in vivo RNA base editing with a wobble-enhanced circular CLUSTER guide RNA

    Recruiting the endogenous editing enzyme adenosine deaminase acting on RNA (ADAR) with tailored guide RNAs for adenosine-to-inosine (A-to-I) RNA base editing is promising for safely manipulating genetic inform...

    Philipp Reautschnig, Carolin Fruhner, Nicolai Wahn in Nature Biotechnology (2024)

  4. No Access

    Article

    CAR-Ts sweep into autoimmunity

    Biotechs are equip** CAR-T cells to destroy B cells — not to treat blood cancers, but to take on multiple sclerosis and a raft of autoimmune disorders.

    Charlotte Harrison in Nature Biotechnology (2024)

  5. No Access

    Article

    Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency

    The use of modified nucleotides to suppress the interferon response and maintain translation of self-amplifying RNA (saRNA), which has been achieved for mRNA, has not yet succeeded. We identify modified nucleo...

    Joshua E. McGee, Jack R. Kirsch, Devin Kenney, Faith Cerbo in Nature Biotechnology (2024)

  6. Article

    Open Access

    Equity in action: The Diagnostic Working Group of The Undiagnosed Diseases Network International

    Rare diseases are recognized as a global public health priority. A timely and accurate diagnosis is a critical enabler for precise and personalized health care. However, barriers to rare disease diagnoses are ...

    Elizabeth Emma Palmer, Helene Cederroth, Mikk Cederroth in npj Genomic Medicine (2024)

  7. No Access

    Article

    Programming tumor evolution with selection gene drives to proactively combat drug resistance

    Most targeted anticancer therapies fail due to drug resistance evolution. Here we show that tumor evolution can be reproducibly redirected to engineer therapeutic opportunity, regardless of the exact ensemble ...

    Scott M. Leighow, Joshua A. Reynolds, Ivan Sokirniy, Shun Yao in Nature Biotechnology (2024)

  8. No Access

    Article

    Evolutionary gambit to defeat drug resistance in cancer

    A therapeutic strategy harnesses evolutionary dynamics to overcome tumor resistance to targeted therapies.

    Andriy Marusyk in Nature Biotechnology (2024)

  9. No Access

    Article

    Editor’s pick: Unnatural Products

    Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Unnatural Products is rewriting the rules for potent oral therapies.

    Michael Eisenstein in Nature Biotechnology (2024)

  10. No Access

    Article

    Editor’s pick: Empress Therapeutics

    Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Empress Therapeutics is reverse-engineering microbial manufacturing.

    Michael Eisenstein in Nature Biotechnology (2024)

  11. Article

    Open Access

    High-throughput discovery of MHC class I- and II-restricted T cell epitopes using synthetic cellular circuits

    Antigen discovery technologies have largely focused on major histocompatibility complex (MHC) class I-restricted human T cell receptors (TCRs), leaving methods for MHC class II-restricted and mouse TCR reactiv...

    Ayano C. Kohlgruber, Mohammad H. Dezfulian, Brandon M. Sie in Nature Biotechnology (2024)

  12. No Access

    Article

    Tracking-seq reveals the heterogeneity of off-target effects in CRISPR–Cas9-mediated genome editing

    The continued development of novel genome editors calls for a universal method to analyze their off-target effects. Here we describe a versatile method, called Tracking-seq, for in situ identification of off-t...

    Ming Zhu, Runda Xu, Junsong Yuan, Jiacheng Wang, **aoyu Ren in Nature Biotechnology (2024)

  13. Article

    Author Correction: High-yield porphyrin production through metabolic engineering and biocatalysis

    Haihong Chen, Yaohong Wang, Weishan Wang, Ting Cao, Lu Zhang in Nature Biotechnology (2024)

  14. No Access

    Article

    Patient-derived mini-colons enable long-term modeling of tumor–microenvironment complexity

    Existing organoid models fall short of fully capturing the complexity of cancer because they lack sufficient multicellular diversity, tissue-level organization, biological durability and experimental flexibili...

    L. Francisco Lorenzo-Martín, Nicolas Broguiere, Jakob Langer in Nature Biotechnology (2024)

  15. Article

    Open Access

    Rare variants at KCNJ2 are associated with LDL-cholesterol levels in a cross-population study

    Leveraging whole genome sequencing data of 1751 individuals from the UK and 2587 Qatari subjects, we suggest here an association of rare variants map** to the sour taste-associated gene KCNJ2 with reduced low-d...

    Niccolò Rossi, Najeeb Syed, Alessia Visconti, Elbay Aliyev in npj Genomic Medicine (2024)

  16. No Access

    Article

    Increasing access to biotech products for animal agriculture in Sub-Saharan Africa through partnerships

    José de la Fuente, Christian Gortázar, Marinela Contreras in Nature Biotechnology (2024)

  17. No Access

    Article

    In vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy

    Natural killer (NK) cells have clinical potential against cancer; however, multiple limitations hinder the success of NK cell therapy. Here, we performed unbiased functional map** of tumor-infiltrating NK (T...

    Lei Peng, Paul A. Renauer, Giacomo Sferruzza, Luojia Yang in Nature Biotechnology (2024)

  18. Article

    Open Access

    Author Correction: Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms

    Rémy Pétremand, Johanna Chiffelle, Sara Bobisse, Marta A. S. Perez in Nature Biotechnology (2024)

  19. No Access

    Article

    Machine learning prediction of prime editing efficiency across diverse chromatin contexts

    The success of prime editing depends on the prime editing guide RNA (pegRNA) design and target locus. Here, we developed machine learning models that reliably predict prime editing efficiency. PRIDICT2.0 asses...

    Nicolas Mathis, Ahmed Allam, András Tálas, Lucas Kissling in Nature Biotechnology (2024)

  20. No Access

    Article

    Effects of the first successful lawsuit against a consumer neurotechnology company for violating brain data privacy

    José M. Muñoz, José Ángel Marinaro, José Antonio Iglesias in Nature Biotechnology (2024)

previous disabled Page of 867